Alterations in follicle development, steroidogenesis, and gonadotropin receptor binding in a model of ovulatory blockade.
Immature female rats treated with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) before gonadotropin-induced follicle development and ovulation ovulate significantly fewer ova compared with controls. This study was designed to investigate potential ovarian-specific mechanisms of TCDD-mediated inhibition of ovulation. Immature hypophysectomized rats were treated with TCDD (32 microg/kg) or corn oil vehicle. Follicle development was initiated by injection of 10 IU PMSG 24 h after TCDD, and ovulation was induced 52 h after PMSG by injection of 10 IU hCG. The number of ova flushed from the oviduct was assessed the morning after hCG injection, and ovaries were collected at multiple times throughout the treatment schedule for histological analysis and analysis of FSH and hCG receptor binding and ovarian cAMP levels. In addition, serum levels of estradiol and progesterone were determined. Control rats ovulated 9.3 +/- 1.5 ova, whereas TCDD-treated rats ovulated 0.6 +/- 0.3. Gonadotropin receptor binding was evaluated 52 h after PMSG at the usual time of hCG injection to induce ovulation. Both FSH binding and hCG binding were significantly reduced in animals treated with TCDD. Serum estradiol levels in control animals were increased by 52 h after PMSG administration. In contrast, serum levels of estradiol in TCDD-treated animals remained low. In response to the ovulatory dose of hCG, serum levels of both estradiol and progesterone increased in control animals. Steroid levels also increased in TCDD-treated animals, but did not reach the peak levels observed in controls. TCDD treatment further resulted in lower ovarian cAMP levels at 52 h post-PMSG and at 5 h post-hCG. Together the data indicate that TCDD treatment altered the ability of the ovary to respond to PMSG, resulting in the development of follicles not comparable to controls (lower gonadotropin binding, lower estradiol production, lower levels of cAMP). It appears that critical steps in the development and maturation of follicles are disrupted by TCDD.
Roby
K F
KF
Center for Reproductive Sciences and Department of Anatomy and Cell Biology, University of Kansas Medical Center, Kansas City 66160, USA. kroby@kumc.edu
D000818:Animals; D002462:Cell Membrane / Q000378:metabolism; D006063:Chorionic Gonadotropin / Q000378:metabolism / Q000494:pharmacology; D004958:Estradiol / Q000096:biosynthesis* / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000378:metabolism; D006064:Gonadotropins, Equine / Q000494:pharmacology; D009929:Organ Size; D006080:Ovarian Follicle / Q000254:growth & development*; D010053:Ovary / Q000033:anatomy & histology / Q000187:drug effects; D010060:Ovulation / Q000187:drug effects; D000072317:Polychlorinated Dibenzodioxins / Q000494:pharmacology; D011374:Progesterone / Q000096:biosynthesis* / Q000097:blood; D051381:Rats; D017207:Rats, Sprague-Dawley; D011967:Receptors, Gonadotropin / Q000378:metabolism*
D006063:Chorionic Gonadotropin; D006064:Gonadotropins, Equine; D000072317:Polychlorinated Dibenzodioxins; D011967:Receptors, Gonadotropin; D011374:Progesterone; D004958:Estradiol; D005640:Follicle Stimulating Hormone